Patents by Inventor Nan-Horng Lin

Nan-Horng Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10745360
    Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases. Methods of using compounds of formula (I), stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
    Type: Grant
    Filed: June 15, 2015
    Date of Patent: August 18, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Nan-Horng Lin, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Mann-Yan Kuo
  • Publication number: 20200115465
    Abstract: The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.
    Type: Application
    Filed: December 30, 2019
    Publication date: April 16, 2020
    Inventors: Nan-Horng LIN, Chiu-Chen HUANG, Chien-Yu CHEN, Kuo-Ching CHU, Chi-Huey WONG, Han-Chung WU
  • Patent number: 10538592
    Abstract: The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: January 21, 2020
    Assignee: CHO PHARMA, INC.
    Inventors: Nan-Horng Lin, Chiu-Chen Huang, Chien-Yu Chen, Kuo-Ching Chu, Chi-Huey Wong, Han-Chung Wu
  • Publication number: 20190328895
    Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): a pharmaceutically acceptable salt thereof wherein Ab is an antibody without glycans (i.e., the protein portion an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2; are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.
    Type: Application
    Filed: November 14, 2017
    Publication date: October 31, 2019
    Applicants: CHO PHARMA INC.
    Inventors: Nan-Horng LIN, Charng-Sheng TSAI, Ting-Chun HUNG, Hong-Yang CHUANG
  • Patent number: 10407673
    Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: September 10, 2019
    Assignees: CHO Pharma Inc., Academia Sinica
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
  • Publication number: 20180298361
    Abstract: A mutant of Endos2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO:1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Application
    Filed: June 18, 2018
    Publication date: October 18, 2018
    Applicants: Academia Sinica
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S. Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
  • Publication number: 20180291109
    Abstract: The present disclosure relates to anti-SSEA4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to SSEA4 molecules and SSEA4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-SSEA4 antibodies and binding fragments induce ADCC or CDC effects in the targeted tumor cells and inhibit and/or reduce the cancer/tumor proliferation. The present disclosure also provides anti-SSEA4 antibodies and binding fragments thereof as a pharmaceutical composition for treating cancer. In addition, the anti-SSEA4 antibodies and binding fragments are useful in the diagnosis of cancers.
    Type: Application
    Filed: August 22, 2017
    Publication date: October 11, 2018
    Inventors: Nan-Horng LIN, Chiu-Chen HUANG, Chien-Yu CHEN, Kuo-Ching CHU, Chi-Huey WONG, Han-Chung WU
  • Publication number: 20180208561
    Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein L is NR8 or O; R1, R2, R3, R4, R5, R6 and R7 are defined herein. Compounds of formula (I) are useful for inhibition of protein kinases.
    Type: Application
    Filed: June 15, 2015
    Publication date: July 26, 2018
    Applicants: Development Center for Biotechnology, DCB-USA LLC
    Inventors: Nan-Horng Lin, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Mann-Yan Kuo
  • Patent number: 10000747
    Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 19, 2018
    Assignees: Academia Sinica, CHO Pharma Inc.
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
  • Publication number: 20180133340
    Abstract: An antibody-drug conjugate (ADC) has a structure represented by Formula (I): [D2-L2-Cn2?yG2-Ab-Sg1?G1-L1-D1]x?? Formula (I) or a pharmaceutically acceptable salt thereof, wherein Ab is an antibody without glycans (i.e., the protein portion of an antibody); G1 and G2 are glycan moieties, which may be the same or different; Cn1 and Cn2 are conjugation moieties, which may be the same or different; L1 and L2 are linker moieties, which may be the same or different; D1 and D2 are drug units which may be the same or different; and x and y are independently an integer from 0 to 8, provided that x+y?0.
    Type: Application
    Filed: November 14, 2017
    Publication date: May 17, 2018
    Applicant: CHO Pharma Inc.
    Inventors: Nan-Horng Lin, Charng-Sheng Tsai, Ting-Chun Hung, Hong-Yang Chuang
  • Publication number: 20180057804
    Abstract: A mutant of EndoS2 includes one or more mutations in the sequence of a wild-type EndoS2 (SEQ ID NO: 1), wherein the one or more mutations are in a peptide region located within residues 133-143, residues 177-182, residues 184-189, residues 221-231, and/or residues 227-237, wherein the mutant of EndoS2 has a low hydrolyzing activity and a high tranglycosylation activity, as compared to those of the wild-type EndoS2. A method for preparing an engineered glycoprotein using the mutant of EndoS2 includes coupling an activated oligosaccharide to a glycoprotein acceptor. The activated oligosaccharide is a glycan oxazoline.
    Type: Application
    Filed: August 23, 2017
    Publication date: March 1, 2018
    Applicants: CHO Pharma Inc., Academia Sinica
    Inventors: Nan-Horng Lin, Lin-Ya Huang, Sachin S Shivatare, Li-Tzu Chen, Chi-Huey Wong, Chung-Yi Wu, Ting Cheng
  • Patent number: 9340558
    Abstract: A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: May 17, 2016
    Assignee: Pain Therapeutics Inc.
    Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
  • Patent number: 9321762
    Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; L1 is —N(R7)—, —O—, —C(S)—, —C(O)—, or —S—; L2 is —N(R8)— or —O—; R1 and R2 are independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C1-C4 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, N,N—(C1-C4 dialkyl)amino C1-C4 alkoxy, N—(C1-C4 alkyl)amino C1-C4 alkoxy, C1-C4 alkanoyl, C1-C4 alkanoyloxy, N—(C1-C4 alkyl)amino, N,N—(C1-C4 dialkyl)amino, C1-C4 alkanoyl amino, or heterocyclyl, wherein C1-C4 alkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R3, R4 and R5 are independently hydrogen, fluorine or chlorine; R6 is C1-C4 alkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or R6 and R8 form a 5-6 membered cyclyl or heterocyclyl.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: April 26, 2016
    Assignee: Development Center for Biotechnology
    Inventors: Mann-Yan Kuo, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Nan-Horng Lin
  • Publication number: 20150158854
    Abstract: A compound for treating a protein kinase-related disease or disorder having a structure of formula (I) wherein G is a heteroaryl, heterocyclic or alkyne; X is N or CH; L1 is —N(R7)—, —O—, —C(S)—, —C(O)—, or —S—; L2 is —N(R8)— or —O—; R1 and R2 are independently hydrogen, halogen, hydroxyl, amino, cyano, nitro, carboxy, C1-C4 alkoxy, C1-C4 alkoxy C1-C4 alkoxy, N,N—(C1-C4 dialkyl)amino C1-C4 alkoxy, N—(C1-C4 alkyl)amino C1-C4 alkoxy, C1-C4 alkanoyl, C1-C4 alkanoyloxy, N—(C1-C4 alkyl)amino, N,N—(C1-C4 dialkyl)amino, C1-C4 alkanoyl amino, or heterocyclyl, wherein C1-C4 alkyl is optionally substituted with one or more substituents selected from fluorine and chlorine; R3, R4 and R5 are independently hydrogen, fluorine or chlorine; R6 is C1-C4 alkyl or aryl, which is optionally substituted with one or more substituents selected from halogen, hydroxyl, amino, cyano, nitro; or R6 and R8 form a 5-6 membered cyclyl or heterocyclyl.
    Type: Application
    Filed: December 11, 2013
    Publication date: June 11, 2015
    Applicant: DEVELOPMENT CENTER FOR BIOTECHNOLOGY
    Inventors: Mann-Yan Kuo, Chu-Bin Liao, Shao-Zheng Peng, Shih-Chieh Yen, Nan-Horng Lin
  • Publication number: 20140113895
    Abstract: A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.
    Type: Application
    Filed: December 20, 2013
    Publication date: April 24, 2014
    Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
  • Patent number: 8653068
    Abstract: A compound or its pharmaceutically acceptable salt, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: February 18, 2014
    Assignee: Pain Therapeutics, Inc.
    Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
  • Patent number: 8614324
    Abstract: A compound or its pharmaceutically acceptable salt, optionally including both individual enantiomeric forms, a racemate, diastereomers and mixtures thereof, composition and method are disclosed that can provide analgesia and reduce inflammation. A contemplated compound has a structure that corresponds to Formula A, wherein the R group substituents, d, e, f, k, n, m, D, E, F, K, G, P, Q, W, and Z are defined within.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: December 24, 2013
    Assignee: Pain Therapeutics, Inc.
    Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
  • Patent number: 8580809
    Abstract: A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within.
    Type: Grant
    Filed: March 8, 2010
    Date of Patent: November 12, 2013
    Assignee: Pain Therapeutics, Inc.
    Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
  • Patent number: 8580808
    Abstract: A compound, its pharmaceutically acceptable salt, a composition containing the same and method of treatment that can provide analgesia and/or reduce inflammation are disclosed. A contemplated compound has a structure that corresponds to Formula A, wherein G, W, Q, Z, D, E, F, K, Y, d, e, f, k, n, m, and circle B and all R groups are defined within.
    Type: Grant
    Filed: October 30, 2009
    Date of Patent: November 12, 2013
    Assignee: Pain Therapeutic, Inc.
    Inventors: Lindsay Burns Barbier, Hoau-Yan Wang, Nan-Horng Lin, Andrei Blasko
  • Patent number: 8148384
    Abstract: Compounds of formula I wherein A1, A2, and A3 are as defined herein are inhibitors of PIM kinase. The compounds of formula I are useful for the treatment of diseases such as cancer.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: April 3, 2012
    Assignee: Abbott Laboratories
    Inventors: Thomas D. Penning, Lisa A. Hasvold, Laura A. Hexamer, Vincent L. Giranda, Nan-horng Lin, Zhi-Fu Tao, Le Wang